The cancer treatments most frequently associated with LV dysfunction are anthracyclines, anti-HER-2 therapy, and targeted anticancer therapies, such as Vascular endothelial growth factor inhibitors (VEGF inhibitors), RAF inhibitors, MEK inhibitors, proteasome inhibitors, BCR-ABL inhibitors (dasatinib, ponatinib), and EGFR/HER2 (osimertinib), as well as radiotherapy [9]. This evidence concerns the gene VEGFA and cancer.